April 14, 2015, New York, NY—Ludwig Cancer Research previewed today the full scope of discoveries to be presented by more than 40 Ludwig scientists at this year’s American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, Pa., April 18–22. Ludwig researchers will deliver presentations of their recent data and participate in symposia, educational sessions and meet-the-expert sessions.
“The annual AACR meeting provides a valuable opportunity for our researchers to exchange new data with colleagues, forge collaborations with scientists across institutions and areas of specialization and share strategies for translating new discoveries into new cancer treatments,” said David Lane, PhD, Scientific Director, Ludwig Institute for Cancer Research.
Ludwig scientists will share their insights on subjects related to both basic and translational research. Basic research presentations will cover areas ranging from genomics to cell signaling to the molecular biology of cancer metastasis, including studies on the expression of obesity-linked genes in prostate cancer, metabolic changes that drive malignancy and the role of immune-suppressing regulatory T cells in cancer. Talks on translational and clinical research will include reports on combining immunotherapies with each other and with targeted therapies, early studies of a novel class of therapeutics (diabodies) to treat ovarian cancer and the development of so-called liquid biopsies, which detect cancer through the capture and analysis of DNA shed into body fluids and blood.
Click here for a comprehensive list of Ludwig’s activities at the Meeting.
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested more than $2.5 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers.